bluebird bio (NASDAQ:BLUE) Rating Increased to Sell at StockNews.com

bluebird bio (NASDAQ:BLUEGet Free Report) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research note issued on Thursday.

Other equities analysts also recently issued reports about the stock. Wedbush lowered their target price on shares of bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a research report on Tuesday, March 19th. Royal Bank of Canada restated a “sector perform” rating and set a $6.00 price target on shares of bluebird bio in a report on Wednesday. Robert W. Baird decreased their price target on shares of bluebird bio from $10.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, December 12th. Wells Fargo & Company decreased their price target on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, William Blair restated a “market perform” rating on shares of bluebird bio in a report on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $5.87.

View Our Latest Stock Analysis on BLUE

bluebird bio Trading Down 6.2 %

NASDAQ BLUE opened at $1.28 on Thursday. bluebird bio has a 1-year low of $0.88 and a 1-year high of $5.53. The company has a market capitalization of $139.96 million, a PE ratio of -1.73 and a beta of 0.75. The firm’s fifty day simple moving average is $1.24 and its 200-day simple moving average is $2.26.

Institutional Investors Weigh In On bluebird bio

Hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its stake in bluebird bio by 6.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 31,773 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 1,862 shares during the period. Mariner LLC lifted its stake in bluebird bio by 12.8% during the fourth quarter. Mariner LLC now owns 17,972 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,043 shares during the period. American International Group Inc. lifted its stake in bluebird bio by 7.1% during the fourth quarter. American International Group Inc. now owns 39,274 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 2,609 shares during the period. Captrust Financial Advisors lifted its stake in bluebird bio by 22.5% during the third quarter. Captrust Financial Advisors now owns 14,679 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 2,700 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of bluebird bio by 15.5% during the second quarter. Tower Research Capital LLC TRC now owns 23,160 shares of the biotechnology company’s stock worth $76,000 after buying an additional 3,104 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

(Get Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

See Also

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.